Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart Disease: Results of the CILON-T (Influence of CILostazol-based triple antiplatelet therapy ON is

详细信息    查看全文

• 作者：Jung-Won Suh MD ; ^† ; ; Seung-Pyo Lee MD ; Kyung-Woo Park MD ; Hae-Young Lee MD ; Hyun-Jae Kang MD ; Bon-Kwon Koo MD ; Young-Seok Cho MD^† ; ; Tae-Jin Youn MD^† ; ; In-Ho Chae MD^† ; ; Dong-Ju Choi MD^† ; ; Seung-Woon Rha MD^‡ ; ; Jang-Ho Bae MD^§ ; ; Taek-Geun Kwon MD^§ ; ; Jang-Whan Bae MD ; Myeong-Chan Cho MD ; Hyo-Soo Kim MD ; ^{hyosoo@snu.ac.kr}
• 关键词：cilostazol ; DES ; platelet reactivity
• 刊名：Journal of the American College of Cardiology
• 出版年：2011
• 出版时间：18 January 2011
• 年：2011
• 卷：57
• 期：3
• 页码：280-289
• 全文大小：958 K

文摘

Objectives

We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES).

Background

The addition of cilostazol on the conventional dual antiplatelet therapy has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention in previous studies.

Methods

In a randomized multicenter trial, we enrolled 960 patients who received DES. They were randomized to receive either dual antiplatelet therapy (DAT) (aspirin and clopidogrel) or triple antiplatelet therapy (TAT) (aspirin, clopidogrel, and cilostazol) for 6 months. Primary end point was the composite of cardiac death, nonfatal myocardial infarction, ischemic stroke, or target lesion revascularization (TLR). Secondary end points were P2Y₁₂ reaction unit (PRU) measured with the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) at discharge and at 6 months after the index procedure. All-cause death, stent thrombosis, and each component of the primary end point at 6 months were other secondary end points. Analysis was done on an intention-to-treat basis.

Results

At 6 months' follow-up, there was no difference in the primary end point between the 2 groups (8.5 % in TAT vs. 9.2 % in DAT, p = 0.74). In secondary end point analysis, the TAT group achieved lower PRU levels than the DAT group both at discharge (206.6 ± 90.3 PRU vs. 232.2 ± 80.3 PRU, p < 0.001) and at 6 months (210.7 ± 87.9 PRU vs. 255.7 ± 73.7 PRU, p < 0.001). In the Cox proportional hazards analysis, lesion length (≥28 mm, hazard ratio [HR]: 2.10, 95 % confidence interval [CI]: 1.25 to 3.52), and PRU level at discharge (every increase in tertile, HR: 1.61, 95 % CI: 1.16 to 2.25) were predictors of the primary end point, but not the use of cilostazol (HR: 0.90, 95 % CI: 0.54 to 1.52).

Conclusions

Despite the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT, TAT did not show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation. (The Efficacy of CILostazol ON Ischemic Complications After DES Implantation [CILON-T]; NCT00776828)